Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology

Cinzia Costa, Michele Romoli, Claudio Liguori, Lucia Farotti, Paolo Eusebi, Chiara Bedetti, Sabrina Siliquini, Elena Nardi Cesarini, Andrea Romigi, Nicola B. Mercuri, Lucilla Parnetti, Paolo Calabresi

Research output: Contribution to journalArticlepeer-review

Abstract

Although amyloid pathology plays a role in epilepsy, little is known about the relationship between beta amyloid and progression to Alzheimer's disease (AD) among patients with late-onset epilepsy of unknown origin (LOEU). This multicenter, observational, prospective study enrolled 40 consecutive nondemented adults diagnosed with LOEU, together with 43 age- and sex-matched healthy controls. All patients completed neuropsychological tests, core CSF AD biomarkers assessment (Aβ1-42, total tau, and phosphorylated tau), and follow-up for a mean of 3 years to verify cognitive decline. Despite age and baseline cognitive performance were similar to healthy controls, patients with LOEU had significant prevalence of CSF pathological Aβ1-42 (<500 pg/mL; 37.5%), 7.5% displaying an AD-like CSF pattern. Moreover, 17.5% of patients with LOEU converted to AD dementia, versus none among healthy controls (p < 0.005). Patients with LOEU with pathological Aβ1-42 had a hazard ratio 3.4 (CI 0.665–17.73) for progression to AD dementia at follow-up. Patients with LOEU have a high prevalence of abnormal CSF Aβ1-42 and progression to AD dementia compared with healthy controls, and therefore should be monitored for cognitive decline.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalNeurobiology of Aging
Volume73
DOIs
Publication statusE-pub ahead of print - Sep 18 2018

Keywords

  • Alzheimer's disease
  • Beta amyloid
  • CSF biomarkers
  • Dementia
  • Epilepsy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Ageing
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology'. Together they form a unique fingerprint.

Cite this